title: [PPI plus bismuth-based quintuple therapy].
authors.affiliation: Kimura GE Clinic.
authors.forename: Ken
authors.initials: K
authors.lastname: Kimura
authors.forename: Takashi
authors.initials: T
authors.lastname: Hiratsuka
authors.forename: Kimihide
authors.initials: K
authors.lastname: Tamura
authors.forename: Hideo
authors.initials: H
authors.lastname: Hiratsuka
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Suzuki
authors.forename: Richard
authors.initials: R
authors.lastname: Bray
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects; D000863:Antacids / Q000008:administration & dosage* / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001729:Bismuth / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008795:Metronidazole / Q000008:administration & dosage*; D008911:Minocycline / Q000008:administration & dosage* / Q000009:adverse effects; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010349:Patient Compliance; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D008911:Minocycline; C010804:bismuth subnitrate; D009853:Omeprazole; D001729:Bismuth